Tomoko Hata1, Masafumi Taniwaki2, Toru Sakura3, Toshihiro Miyamoto4, Kensuke Usuki5, Shinji Tetsuo6, Ei Leen Liew7, Kiyohiko Hatake8 (1.Dept. of Hematology, Nagasaki University Hospital, Nagasaki, Japan, 2.Kyoto Prefectural University of Medicine, Kyoto, Japan, 3.Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan, 4.Department of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan, 5.Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 6.Department of Clinical Management, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, 7.Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan, 8.Department of Hematology, International University of Health and Welfare, Tokyo)
Session information
Oral Session
Oral Session 2-11B AML: Novel therapeutic targets
Sat. Oct 13, 2018 10:10 AM - 11:10 AM No.11 (Osaka International Convention Center, 10F 1004-5)
Chair: Yoichi Imai (Research Hospital, The Instisute of Medical Science, The University of Tokyo, Japan)
Jo Ishizawa1, Takenobu Nii2, Ran Zhao1, Lauren Heese1, Yuki Nishida1, Gautam Borthakur1, Kensuke Kojima1,3, Joshua Allen4, Varun Prabhu4, R Eric Davis5, Michael Andreeff1 (1.Dept. of Leukemia, UT MD Anderson, Houston, USA, 2.Kyushu Univ., Kyushu, Japan, 3.Div. Hematol., Resp Med, and Oncol., Saga Univ., Saga, Japan, 4.Oncoceutics, Inc., Philadelphia, USA, 5.Dept. of Lymphoma/Myeloma, UT MD Anderson, Houston, USA)
Tomoko Hyoda1, Yuya Kunisaki2, Kentaro Hosokawa2, Tsuyoshi Hirota3, Kazuhito Gotoh4, Daiki Setoyama4, Dongchon Kang4, Fumio Arai2 (1.Health Science, Kyushu Univ., Fukuoka, Japan, 2.Stem Cell Biology, Kyushu Univ., Fukuoka, Japan, 3.Transformative Bio-Molecules, Nagoya Univ., Japan, 4.Clinical Chemistry and Laboratory Medicine, Kyushu Univ., Japan)
Naru Sato1, Susumu Goyama1, Xiaoxiao Liu1, Takeshi Fujino1, Taishi Yonezawa1, Hitoshi Takizawa2, Satoshi Yamasaki3, Tatsuhiro Shibata3, Toshio Kitamura1 (1.Division of Cellular Therapy, IMS,Tokyo Univ., 2.IRCMS, Kumamoto Univ.,, 3.Laboratory of Molecular Medicine, Human Genome Center, IMS,Tokyo Univ.)
Yasutaka Hayashi1, Susumu Goyama1, Xiaoxiao Liu1, Shiori Shikata1, Yosuke Tanaka1, Tomofusa Fukuyama1, Akiko Matsumoto2, Satoshi Yamasaki2, Tatsuhiro Shibata2, Hitoshi Takizawa3, Toshio Kitamura1 (1.Cellular Therapy, IMSUT, Tokyo Univ., Tokyo, Japan, 2.Laboratory of Molecular Medicine, HGC, IMSUT, Tokyo Univ., Tokyo, Japan, 3.International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan)
Taishi Yonezawa1, Hirotaka Takahashi2, Shiori Shikata1, Tomofusa Fukuyama1, Yosuke Tanaka1, Kenneth Kassenbrock3, Tatsuya Sawasaki2, Toshio Kitamura1, Susumu Goyama1 (1.The institute of Medical Science, The University of Tokyo, Japan, 2.Proteo-Science Center (PROS)., Ehime University., Ehime, Japan, 3.Department of Pathlogy, The Univeresity of Colorado Anschutz Medical Campus)